Novel coronavirus pneumonia (COVID-19)
Conditions
Interventions
Experimental group:Lopinavir and Ritonavir Tablets
control group:Routine symptomatic support treatment
Sponsors
Jingzhou First People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Sign the written informed consent; 2. Aged 18-80 years old; 3. Meet the diagnostic criteria for novel coronavirus infection(trial version sixth), confirmed by combining with the epidemiological history, clinical manifestations and etiology examination; 4. Course of disease within 14 days after onset.
Exclusion criteria
Exclusion criteria: 1. Patients who are participating in clinical trials of other drugs; 2. Pregnant or lactating women; 3. ALT / AST > 2-fold ULN; 4. Expected survival time < 1 week; 5. With serious liver disease; 6. Patients taking orally anti-tumor drugs or immunomodulatory drugs for a long time; 7. Patients who are participating in other clinical trials; 8. The researchers think that other reasons are not suitable for clinical trials.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Endotracheal intubation rate;mortality;Ratio of virus nucleic acid detection to negative; | — |
Secondary
| Measure | Time frame |
|---|---|
| Inflammatory markers;Clinical symptoms;Liver and kidney function; | — |
Countries
China
Contacts
Public ContactWei Xiao
Jingzhou First People's Hospital
Outcome results
None listed